Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Completed · Phase 3

Conditions studied: Prediabetic State

In brief

The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.

Key facts

Study ID

NCT00237250

Run by

Novartis

People needed

171

Starts

2005-10-01

Expected to finish

2006-07-01

Last updated by the study team

2012-05-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Blood glucose criteria must be met
• Body mass index (BMI) in the range 23-45

You may not qualify if…

• Diagnosis of diabetes
• Serious cardiovascular events within the past 6 months
• Use of insulin or any oral antidiabetic agent
• Other protocol-defined exclusion criteria may apply

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.